Table 4 Relationship between drug allocation and age and gender in patients who survived more than 30 days.
From: Use of evidence-based pharmacotherapy after myocardial infarction in Estonia
Drug | Male OR (95% CI) | Female OR (95% CI) | 20-39 years OR (95% CI) | 40-59 years OR (95% CI) | 60-79 years OR (95% CI) | 80-99 years OR (95% CI) |
|---|---|---|---|---|---|---|
BB | 1.00 | 0.79 (0.61-1.02) | 1.00 | 0.56 (0.17-1.91) | 0.97 (0.29-3.19) | 1.93 (0.58-6.47) |
ACE/ARB | 1.00 | 0.89 (0.70-1.14) | 1.00 | 2.49 (1.67-3.70)** | 5.69 (3.66-8.82)** | |
Statins | 1.00 | 1.19 (0.55-2.57) | 1.00 | 0.88 (0.38-2.06) | 0.17 (0.02-1.37) | |
BB & ACE/ARB | 1.00 | 1.15 (0.99-1.33) | 1.00 | 0.79 (0.37-1.70) | 1.21 (0.57-2.57) | 1.92 (0.89-4.14) |
BB & statins | 1.00 | 0.68 (0.49-0.92)** | 1.00 | 0.66 (0.19-2.21) | 0.81 (0.24-2.66) | 0.28 (0.08-1.06) |
ACE/ARB & statins | 1.00 | 0.63 (0.44-0.89)** | 1.00 | 0.48 (0.18-1.28) | 0.32 (0.12-0.84)** | 0.19 (0.06-0.58)** |
BB & ACE/ARB & statins | 1.00 | 1.21 (1.05-1.39)** | 1.00 | 1.94 (1.00-3.77) | 1.02 (0.53-1.96) | 0.28 (0.14-0.55)** |